Firm stops trials of obesity drug

Sanofi-Aventis has discontinued all trials of its anti-obesity drug rimonabant (Acomplia), which was suspended by the European Medicines Agency last month.

At the time of the suspension, Sanofi-Aventis said it saw the suspension as temporary and that it hoped ongoing studies would provide additional evidence for the product's safety and benefit in patients with diabetes and cardiovascular disease.

The company has now announced that it has decided to discontinue the ongoing rimonabant clinical development programme in all indications.

The decision has been taken 'in light of recent demands by certain national health authorities', a spokesman said.

'As a result the feasibility of the global clinical development programme has been compromised.'

The EMEA withdrew the European Marketing Authorisation for Acomplia after an assessment of the drug's benefits and risks showed an increased risk of psychiatric disorders patients.

The agency said it believed that these side-effects could not be adequately addressed by risk minimisation measures.

tom.moberly@haymarket.com

Comment below and tell us what you think

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Practices handed one-month opt-out window as revamped network DES unveiled

Practices handed one-month opt-out window as revamped network DES unveiled

NHS England has unveiled a revamped DES package for 2020/21 confirming new targets,...

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered huge rise in face-to-face consultations in week before NHS England letter

GPs delivered a huge increase in face-to-face appointments in the week before NHS...

RCGP facing legal action over stance on assisted dying

RCGP facing legal action over stance on assisted dying

The RCGP is facing legal action over its decision to remain opposed to assisted dying...

Medeconomics Live aims to help practices thrive under the new GP contract

Medeconomics Live aims to help practices thrive under the new GP contract

The one-day, virtual Medeconomics Live conference aims to provide practices with...

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GPs face wave of abuse and complaints after NHS England face-to-face appointments claims

GP practices have faced a wave of abuse and complaints after a letter from NHS England...

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

Government denies plan to make GPs 'gatekeepers' of COVID-19 testing

The government has denied plans to make GPs 'gatekeepers' of the struggling COVID-19...